Business

SK Bioscience announced that it has partnered with nonprofit research organization IAVI on development of an antiviral nasal spray based on a protein developed by David Baker at the University of Washington. The company noted that it will get $2.2 million out of a grant by the Bill & Melinda Gates Foundation to IAVI for the project. The Gates Foundation also … [Read more...] about SK Bioscience partners with IAVI and University of Washington on development of binder protein nasal spray against COVID-19

Receptor Life Sciences said that it has closed a $9.7 million Series A-1 financing and will use the proceeds for clinical development of its RLS103 cannabidiol DPI. RLS103 is based on MannKind Corporation's Technosphere particle engineering technology, which Receptor licensed for use with its cannabinoid products in 2016.  The company is developing the inhaled CBD … [Read more...] about Receptor Life Sciences raises $9.7 million for development of RLS103 dry powder CBD

The Lundquist Institute for Biomedical Innovation has announced that the Bill & Melinda Gates Foundation has awarded a 2-year grant of $471,858 to principal investigator Frans Walther for further development of an aerosolized synthetic lung surfactant for the treatment of respiratory distress syndrome (RDS) in newborn babies. In March 2021, the institute announced … [Read more...] about Gates Foundation provides grant for development of aerosolized surfactant for the treatment of RDS in newborns

The Indian Ministry of Science & Technology's Technology Development Board (TDB) has signed a development and commercialization agreement with Hyderabad-based Sapigen Biologix, committing ₹100 crores to development of a novel intranasal vaccine against COVID-19 and a vaccine against malaria, the ministry said. The ministry said that the TDB funding will cover … [Read more...] about Sapigen Biologix gets funding from TDB for development of intranasal COVID-19 vaccine

OxyContin maker Purdue Pharma will provide an additional $11 million to non-profit Harm Reduction Therapeutics (HRT) for continued development of HRT's HRT001 naloxone nasal spray for the reversal of opioid overdose. The additional funding was approved by the court overseeing Purdue's bankruptcy. Purdue began funding HRT in 2018, and in 2020, Purdue announced that it … [Read more...] about Harm Reduction Therapeutics gets additional $11 million for development of naloxone nasal spray

Virpax has announced an expansion of its license agreement with Nanomerics to add worldwide rights to AnQlar nasal spray, an antiviral mucoadhesive polymer derived from chitosan. The original license agreement, which was announced in August 2020, included North American rights only. According to Nanomerics, the additional funds paid by Virpax for the expanded license … [Read more...] about Virpax gets worldwide rights to Nanomerics’ AnQlar antiviral nasal spray

Funds managed by Oaktree Capital Management will provide $100 million in funding to Impel NeuroPharma, with $50 million of that amount in cash up front as part of a royalty agreement on net sales of Trudhesa dihydroergotamine (DHE) nasal spray and the other $50 million in the form of a credit facility. The FDA approved Trudhesa for the treatment of migraine in … [Read more...] about Impel Neuropharma secures $100 million for continued commercialization of Trudhesa nasal spray